- Home
- NODK vs PEPG Comparison
NODK vs PEPG Comparison
Compare NODK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- PEPG
- Stock Information
- Founded
- NODK 1946
- PEPG 2018
- Country
- NODK United States
- PEPG United States
- Employees
- NODK N/A
- PEPG N/A
- Industry
- NODK Property-Casualty Insurers
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- PEPG Health Care
- Exchange
- NODK Nasdaq
- PEPG Nasdaq
- Market Cap
- NODK 327.3M
- PEPG 118.3M
- IPO Year
- NODK 2017
- PEPG 2022
- Fundamental
- Price
- NODK $14.66
- PEPG $2.72
- Analyst Decision
- NODK
- PEPG Buy
- Analyst Count
- NODK 0
- PEPG 3
- Target Price
- NODK N/A
- PEPG $14.67
- AVG Volume (30 Days)
- NODK 14.9K
- PEPG 270.5K
- Earning Date
- NODK 11-07-2024
- PEPG 03-05-2025
- Dividend Yield
- NODK N/A
- PEPG N/A
- EPS Growth
- NODK N/A
- PEPG N/A
- EPS
- NODK N/A
- PEPG N/A
- Revenue
- NODK $391,655,000.00
- PEPG N/A
- Revenue This Year
- NODK N/A
- PEPG N/A
- Revenue Next Year
- NODK N/A
- PEPG N/A
- P/E Ratio
- NODK N/A
- PEPG N/A
- Revenue Growth
- NODK 22.91
- PEPG N/A
- 52 Week Low
- NODK $12.71
- PEPG $2.67
- 52 Week High
- NODK $17.24
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- NODK 31.57
- PEPG 23.94
- Support Level
- NODK $14.35
- PEPG $3.69
- Resistance Level
- NODK $15.73
- PEPG $4.48
- Average True Range (ATR)
- NODK 0.35
- PEPG 0.33
- MACD
- NODK -0.12
- PEPG -0.06
- Stochastic Oscillator
- NODK 16.32
- PEPG 2.77
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.